DCIS is a non-invasive or pre-invasive breast cancer, meaning the cancer cells are confined to the milk ducts and haven’t ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

Cancer Antibody Drug Conjugates Treatment Market USD 50 Billion Opportunity Says Kuick Research. Delhi, July 11, 2025 (GLOBE ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

End of Phase 2 Meeting with FDA scheduled for August 27, 2025 to review OST-HER2 recurrent, pulmonary metastatic osteosarcoma programScientific Advice Meetings confirmed with global regulators in majo ...

The update strengthens IBTROZI's position as a next-generation treatment in a rare, aggressive lung cancer that often spreads ...

The ASX 200 is up 0.81% to 8607.40 points at 1pm AEST, supported by strength in heavyweight miners and banks. Property stocks ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary - Cancer rates are rising everywhere ...

Detailed price information for Mustang Bio Inc (MBIO-Q) from The Globe and Mail including charting and trades.

The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in the coming years. Several factors ...

Breast cancer remains the ... you to new people and give you a positive perspective on life. Side effects from treatment may ...